The race to develop transcatheter systems for tricuspid regurgitation (TR) continues, and early-stage report cards are in for several investigational devices. Progress with transcatheter tricuspid ...
One-year follow-up data suggest that a novel transcatheter tricuspid valve replacement (TTVR) device may provide another potential alternative to surgery for patients with severe tricuspid ...
Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Co-Founder and ...
Favorable mortality and heart failure hospitalization rates, along with improved functional status, observed among recipients of LuX-Valve device for severe symptomatic tricuspid regurgitation. Single ...
TRINITY is a global prospective, multicenter, single-arm clinical trial, which primarily aims to evaluate the safety and efficacy of LuX-Valve Plus in application on patients with severe tricuspid ...
DETROIT (April 12, 2023) – Henry Ford Hospital structural heart interventional cardiologists Pedro Villablanca, M.D., and Brian O’Neill, M.D., are the first in the U.S. to successfully implant the new ...
BEIJING, June 2, 2025 /PRNewswire/ -- Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company, recently released 30-day follow-up results of ...
MAPLE GROVE, Minn.--(BUSINESS WIRE)--VDYNE, Inc. (“VDYNE” or “the Company”), a privately held medical device company developing next generation transcatheter valve replacement technologies, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results